Listen and follow our podcasts on:

Bayer

In this podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented at the ILCA and ESMO congresses, 2022. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

 

 

 

Dr Matthias Pinter works at the Medical University of Vienna in Austria where he also received both his MD and PhD. He is board-certified for Internal Medicine and Gastroenterology and Hepatology. Since 2017, he has led the hepatocellular carcinoma programme and research group at the Division of Gastroenterology and Hepatology at the Medical University of Vienna. His main research interests include the systemic treatment of liver cancer, particularly the identification of prognostic markers and scores that may help to identify patients most likely to benefit from specific therapies. To broaden his knowledge and expertise in basic research and experimental oncology, he worked as a research fellow and postdoc at renowned institutions, including the University of Bern in Switzerland and the Massachusetts General Hospital/Harvard Medical School in the United States. He has published numerous original papers and review articles on liver cancer in prestigious peer-reviewed journals covering the categories oncology, gastroenterology and hepatology, and radiology.

Assoc. Prof. Matthias Pinter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Ipsen, Eisai, Lilly, MSD and Roche.

Prof. Dr Jeroen Dekervel is a GI oncologist working at the Digestive Oncology Unit of UZ Leuven, Belgium. In daily clinical practice, he treats all kinds of gastrointestinal malignancies at one of the largest clinics of its kind in Europe. He is an associate professor at the KU Leuven, where his research focuses on unraveling the reasons for success and failure of immunotherapies in hepatocellular carcinoma, using a variety of single cell techniques. He is a member of ESMO and ASCO, as well as part of the ESMO upper GI faculty as a mentee.

Prof. Dr Jeroen Dekervel has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Amgen, BMS, Eisai, Ipsen, Lilly, Merck, MSD, Roche, Novartis and Servier. 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA
podcast Podcast
Oncology 
Understanding rare non-small cell lung cancer (NSCLC) alterations

Insights and support for patients

Experts
Dr Joshua Sabari, Debra Montague
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim